Olatinib maleate can be used as an organic synthesis intermediate and pharmaceutical intermediate, mainly used in laboratory research and development process and pharmaceutical and chemical production process.
*The following content is generated by AI and is for reference only.
Oclacitinib Maleate, chemically designated as PF-03394197, is a potent and selective Janus kinase (JAK) inhibitor developed primarily for veterinary medicine. Its molecular formula is C28H35ClN8O6, with a molecular weight of approximately 595.08 g/mol. The substance is identified by the CAS number 958646-73-4. Structurally, it consists of the active free base Oclacitinib complexed with maleic acid to enhance stability and solubility for pharmaceutical formulation.
This compound functions by selectively inhibiting JAK1 and JAK3 enzymes, which are critical signaling pathways involved in the production of cytokines responsible for inflammation and pruritus (itching). By blocking these pathways, Oclacitinib Maleate effectively interrupts the immune response associated with allergic reactions without broadly suppressing the entire immune system, thereby minimizing the risk of severe immunosuppression compared to traditional corticosteroids. It is widely recognized and approved for the management of atopic dermatitis and control of pruritus associated with allergic dermatitis in dogs. Clinical studies have demonstrated rapid onset of action, often reducing itching within hours of administration, significantly improving the quality of life for affected animals and their owners.
The drug is typically administered orally in tablet form and has become a cornerstone therapy in veterinary dermatology for managing chronic skin conditions that do not respond adequately to conventional treatments. While highly effective, its use requires careful monitoring, particularly regarding potential side effects such as increased susceptibility to infections or gastrointestinal disturbances, although these are generally rare when used according to label instructions. As a synthetic small molecule, Oclacitinib Maleate represents a significant advancement in targeted immunomodulation, offering a safer alternative to long-term steroid use. Its development underscores the growing trend of applying precision medicine principles to animal health, providing veterinarians with a robust tool to manage inflammatory diseases efficiently. Continued research aims to expand its application profile, potentially exploring efficacy in other species or different inflammatory conditions, solidifying its role as a vital asset in modern veterinary pharmacotherapy.